IGEA announces launch of Alz1

Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.

“The digital revolution has sparked a shift in the way consumers think about and access healthcare,” said Diego Mortillaro, CEO of IGEA. “Rather than waiting and reacting to symptoms of disease, consumers are enhancing their focus on monitoring and reduction of risk factors to improve their health and wellness – and they increasingly want the opportunity to do so from the comfort of their own homes. Our Alz1 solution empowers consumers with the information they need to take steps now that can reduce a major risk factor for a disease nearly 6 million Americans are living with today – Alzheimer’s disease.”

Alz1, available exclusively online, is an easy-to-use blood collection kit designed to measure free copper, a modifiable risk factor that can contribute to the onset and progression of Alzheimer’s disease. Through the identification of free copper, the test empowers users to take proactive control – like lifestyle and dietary changes – of their health and well-being. With no doctor’s appointment, prescription or need to bill insurance, Alz1 ensures this area of strategic proactive healthcare is easier than ever.

When the test results show high free copper levels, users have the option to choose the Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream, including free copper. Containing glutathione and oleuropein, among other ingredients, the Alz1 Tab could be useful in protecting against neurodegeneration.

Following a seamless order experience, Alz1 kit is delivered right to a customer’s door. From there, customers simply register the kit and follow the instructions to collect the blood sample. Using a pre-paid envelope, customers send the sample back to IGEA’s CLIA-certified and CAP-accredited laboratory, where it will be quickly analysed. Test results will be shared exclusively with users through Alz1’s secure online platform.

“In recent years, several programs to develop drugs for the treatment of Alzheimer’s disease were discontinued,” said Mortillaro. “Compounding the issue, the Alzheimer’s Association revealed that the number of Americans who have Alzheimer’s is expected to increase to 14 million (from 5.8 million today) by 2050. Consequently, we expect proactive healthcare habits are important to help protect yourself from the most common cause of dementia. Our mission is to find better, more convenient ways to help consumers have a positive impact on proven risk factors of Alzheimer’s.”

About Alz1

Alz1, a US-based brand of IGEA, leverages the deep scientific knowledge of IGEA’s scientific advisory board members to reinvent proactive healthcare in Alzheimer’s disease by capitalizing on digital economy opportunities and recent healthcare industry trends. The simple and convenient Alz1 kit is an at-home blood test designed to detect free copper in the bloodstream – high levels of which indicate one of the risk factors for Alzheimer’s disease. The Alz1 Tab, a natural dietary supplement, helps decrease heavy metal contents, including free copper, in the bloodstream. For information about Alz1, Alz1 Tab or why detecting free copper in the bloodstream is important, please visit https://alz1.com/

About IGEA

IGEA is a health-tech group focused on measure and control of risk factors related to life-threatening diseases. IGEA commercialize Alz1, a test kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream and Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively.

IGEA is listed on the SIX Swiss Exchange under the ticker ‘IGPH’ and is headquartered in Hoofddorp, the Netherlands. The Group’s principal place of business is in the US.

For further information, please visit the IGEA website at https://www.igeapharma.nl/

IGEA Pharma N.V. Investor Relations: https://www.igeapharma.nl/investors-relations/

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.

The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.

Contact

IGEA Pharma N.V.

Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands

+31 23 568 94 94

Share this post